Overview

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled
Phase:
Phase 2
Details
Lead Sponsor:
Eyetech Pharmaceuticals